AI brief from 2 reports (GOV.UK news and announcements)
MHRA advancing MedTech and AI regulation agenda at AdvaMed 2026; approves plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome
The UK Medicines and Healthcare products Regulatory Agency (MHRA) outlined its next phase of MedTech and AI regulation to US industry at AdvaMed 2026, and subsequently authorised plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome. 1,2
MHRA presented its next phase of MedTech and AI regulation for the US market at AdvaMed 2026. 1
MHRA authorised plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome. 2
2026-10-19: MHRA presents MedTech and AI regulation agenda at AdvaMed 2026. 1
2026-10-19: MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome. 2
The reports
| # | Report | Outlet | Date |
|---|---|---|---|
| 1 | UK regulator brings new AI and MedTech agenda to AdvaMed UK’s Medicines and Healthcare products Regulatory Agency (MHRA) sets out its next phase of MedTech and AI regulation to US industry leaders at AdvaMed 2026. | GOV.UK news and announcements | |
| 2 | MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 19 October 2026, authorised plozasiran (Redemplo) | GOV.UK news and announcements |
What the AI left out (1)
- No further details on regulatory terms or clinical data are provided beyond the two items.